The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures. 

Witness Ge Bai, an associate professor at Johns Hopkins University’s Carey Business School and Bloomberg School of Public Health, said Congress should require drug makers to disclose their financial relationships with independent patient assistance programs and patient advocacy organizations and their free drug samples to clinicians. She said these transactions “can undermine the best interests of patients and their insurance plans while benefiting drug manufacturers financially.”   

Juliana Keeping, communications director for Patients for Affordable Drugs and the mother of a child with cystic fibrosis, also urged Congress to “eliminate the need for patient assistance programs by making drug costs affordable and cost-sharing manageable.” 

Tara O’Neill Hayes, director of human welfare policy for the American Action Forum, called for changes to the Part D benefit to remove “perverse incentives for insurers and drug manufacturers to benefit from high-cost drugs.” 

Steven Tananbaum, a senior fellow for the Council on Foreign Relations, recommended Congress remove incentives for drug makers to move profits and production offshore.

In December, the House of Representatives passed H.R. 3, legislation that would make changes to the Medicare program in an effort to lower prescription drug prices. 

Subcommittee Ranking Member Devin Nunes, R-Calif., said both parties “can work together to lower drug prices for families without reducing cures, but H.R. 3 is not the answer.” Instead, he voiced support for H.R. 19

Related News Articles

President Trump Friday signed three executive orders aimed at lowering the price of prescription drugs, with actions targeting federally qualified health…
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…